ADOCY:OTC-Adocia SA (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 13.10

Change

0.00 (0.00)%

Market Cap

USD 0.09B

Average Target Price

USD 20.00 (+52.67%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The company's proprietary BioChaperone technological platform is designed and developed to enhance the effectiveness and/or safety of therapeutic proteins. Its clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analog lispro; BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro; and BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide M1Pram. The company's clinical pipeline also includes BioChaperone Glucagon, which is an aqueous formulation of human glucagon for the treatment of hypoglycemia. Its preclinical pipeline includes BioChaperone LisPram), which is a combination of rapid human insulin analogues and Pramlintide; BioChaperone Glargine GLP1 that is a combination of insulin glargine with GLP-1 receptor agonists for the treatment of diabetes; and BioChaperone Glucagon GLP1, which is a combination of glucagon and a GLP-1 receptor agonist for the treatment of obesity. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was founded in 2005 and is headquartered in Lyon, France.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

+0.39 (+0.54%)

USD167.25B 29.56 2.87
CSLLY CSL Limited

-0.79 (-0.75%)

USD95.39B 45.82 26.33
CMXHF CSL Limited

+0.66 (+0.32%)

USD94.93B 45.25 26.33
GNMSF Genmab A/S

-3.48 (-0.79%)

USD28.57B 122.84 3.24
UCBJF UCB SA

+4.10 (+3.99%)

USD19.98B 19.05 17.47
SBMFF Sino Biopharmaceutical Limited

+0.02 (+1.98%)

USD19.68B 30.61 2.97
UCBJY UCB SA

+0.08 (+0.15%)

USD19.56B 19.79 17.47
SBHMY Sino Biopharmaceutical Limited

N/A

USD17.93B 28.00 2.97
PPTDF PeptiDream Inc

N/A

USD7.06B 260.99 1.65
ABCZF Abcam plc

-0.25 (-1.06%)

USD5.29B 58.90 114.95

ETFs Containing ADOCY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.00% 59% F 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.00% 59% F 70% C-
Trailing 12 Months  
Capital Gain 5.82% 43% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.82% 43% F 47% F
Trailing 5 Years  
Capital Gain -81.28% 24% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -81.28% 24% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain -30.46% 11% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.46% 10% F 4% F
Risk Return Profile  
Volatility (Standard Deviation) 25.18% 89% B+ 65% D
Risk Adjusted Return -120.99% 4% F 1% F
Market Capitalization 0.09B 71% C- 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.60 49% F 43% F
Price/Book Ratio 3.72 63% D 31% F
Price / Cash Flow Ratio -9.75 66% D 80% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -71.42% 40% F 15% F
Return on Invested Capital -37.31% 38% F 15% F
Return on Assets -25.26% 64% D 23% F
Debt to Equity Ratio 66.04% 14% F 29% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.31 34% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector